Group items tagged

The King's Fund has published an in-depth analysis highlighting the priorities that the government's new 10-year health plan should address to combat health inequalities. This plan, currently being developed by the Department of Health and Social Care (DHSC) and NHS England, will significantly shape the long-term future of the NHS. The independent think tank emphasises that a core focus of this new plan should be to enable the NHS to better address health inequalities and support people with the worst health outcomes. Sarah Woolnough, CEO of The King's Fund, explained: "Health inequalities are avoidable, unfair, and systematic differences in health between different groups of people, and they reflect broader societal issues such as those related to income, housing, gender, ethnicity or disability." "Supporting the health and care system to do more to tackle these differences has been a strategy priority for the Fund over the past five years." Drawing on its extensive work on health inequalities in the last five years, the charity has outlined seven key priorities that should shape the 10-year health plan:

A new report has highlighted that the public places a higher value on medicines for severe medical conditions, such as terminal cancer, than the thresholds currently used by the National Institute for Health and Care Excellence (NICE). The study, conducted by the Office of Health Economics (OHE), found a misalignment between NICE's current 'severity modifier'-which determines whether a medicine is recommended for coverage on the National Health Service (NHS)-and the UK public's preference for prioritising health gains for more severe diseases. The research, commissioned and funded by the Association of the British Pharmaceutical Industry (ABPI), also indicated that the public is willing to pay more for medicines used to treat patients with severe disease. Titled 'Understanding Societal Preferences for Priority by Disease Severity in England and Wales,' the report suggested that NICE's current severity modifier may be limiting access to innovative treatments for NHS patients. The ABPI has called on the government and NICE to adopt a more flexible approach when assessing medicines for severe conditions.